Ruxolitinib for Chronic Myeloid Leukemia (CML) With Minimal Residual Disease (MRD)
This study is not yet open for participant recruitment.
Verified December 2012 by M.D. Anderson Cancer Center
Sponsor:
M.D. Anderson Cancer Center
Collaborator:
Incyte Corporation
Information provided by (Responsible Party):
M.D. Anderson Cancer Center
ClinicalTrials.gov Identifier:
NCT01751425
First received: December 14, 2012
Last updated: December 17, 2012
Last verified: December 2012
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Study Status: | This study is not yet open for participant recruitment. |
|---|---|
| Estimated Study Completion Date: | No date given |
| Estimated Primary Completion Date: | May 2019 (Final data collection date for primary outcome measure) |